The Unified Biosystem for Drug Discovery

In 2026, the biggest constraint in pharmaceutical AI is no longer compute. It is not even model architecture. It is data — but not in the way we traditionally think about it. For decades, drug discovery has been focused on a simple premise: learn from what works.

"We train for success, but biology reveals constraints through failure.”

That mismatch is now the central bottleneck in AI-driven drug discovery.

Nearly 90% of molecules entering clinical development fail.

Most do not fail because we cannot design molecules. They fail because we cannot predict how biology will reject them — through toxicity, metabolic breakdown, or lack of efficacy.

Here lies the paradox: our models are trained primarily on the 10% that succeed, while the 90% that fail — the most informative signal in all of drug discovery — remains fragmented, underutilized, or entirely absent from training data.

This is not merely a data-volume problem. It is a data-composition problem. Models built on success-only datasets exhibit systematic blind spots:

• Structural Bias: Models overfit to known scaffolds.
• False Positives: High error rates at the hit identification stage.
• Silent Failure: Catastrophic late-stage attrition where costs are highest.

As we will see in our case study, these silent failures are often hidden ‘in the house’ — not the clinic.

SECTION 01 · The Strategic Pivot
Negative Learning (NL)

Cross-domain biological systems such as the microbiome, toxicology, and environmental exposure datasets provide structured failure signals that are directly relevant to human biology. These datasets provide exactly what pharmaceutical AI lacks for learning large-scale negative outcomes and context-specific biological responses.

Current drug discovery models possess an incomplete map; they know where success lies, but not where failure begins. Transitioning from positive-only to Negative Learning (NL) — balanced learning from both success and failure — is the foundational corrective the industry must now adopt.

Why Negative Data is Non-Negotiable

For AI to be predictive rather than just descriptive, it requires contrastive learning. By intentionally integrating negative data, we enable AI to:

• Establish Precise Decision Boundaries: Learning exactly where a chemical scaffold transitions from “therapeutic” to “metabolic failure.”
• Improve ADMET Predictions: Identifying structural features that consistently lead to absorption or toxicity problems before a single molecule is synthesised.
• De-risk Clinical Attrition: Moving from a “make-then-test” cycle to a “predict-then-make” paradigm, saving years of wasted effort.

Table 1 · The Power of Negative Learning

SECTION 02 · WHY THIS PROBLEM IS CRITICAL RIGHT NOW
The 2026 Inflection Point: Why the Bottleneck Has Become Existential

For years, the industry operated under the assumption that better algorithms alone would solve drug attrition, but in 2026, that hope is hitting a wall. While generative models have scaled in complexity, clinical failure rates remain stubbornly high because our models lack an understanding of where biology actually breaks. As we reach this “epistemic limit,” more compute is no longer the solution.

“More compute alone will not solve it. Better architectures alone will not solve it. The bottleneck is epistemic.”

Several forces are converging to make this problem acute right now:

• Regulatory pressure is intensifying. Agencies increasingly expect AI-assisted submissions to demonstrate mechanistic interpretability, not just predictive accuracy. Models trained on success-only data cannot meet this standard.
• The low-hanging fruit has been picked. Easy target classes are saturated. The next generation of therapeutics requires venturing into poorly understood biological territories — precisely where failure-informed models have the greatest advantage.
• Omics data is exploding but remains noisy. Genomics, transcriptomics, and proteomics have generated unprecedented volume, yet the signal-to-noise challenge is worse than ever. Only models with robust failure context can separate meaningful biomarkers from biological noise.
• The microbiome has entered clinical reality. Following landmark research mapping how gut bacteria mediate the metabolism of hundreds of oral drugs, the field now recognises that ignoring microbial biology is no longer scientifically defensible.

The pivot is now mandatory: we must move from modeling molecules in isolation to modeling them within the One Health framework — the recognition that human health, environmental systems, and microbial ecosystems are deeply interconnected.

SECTION 03 · EVIDENCE FROM THE FIELD
The Evolved Systems Health Data Architecture (Beyond Multi-Omics)

The frontier of drug discovery is no longer defined by “more data,” but by a hierarchical architecture that integrates orthogonal biological signals into a unified, causal framework. This system moves beyond traditional multi-omics to map the actual “temporal detection layer” of failure.

1. The Microbial Engine (The Host-Microbiome System)

Research by Zimmermann et al. established that drug response is a property of the host-microbiome system, not the molecule alone. Microbial enzymes systematically biotransform drugs, meaning a “success” in one microbial context is a “toxic failure” in another.

2. Pre-Clinical Stress Signatures (Early Detection)

Failure is observable long before it manifests in the clinic. Platforms like LINCS L1000 have identified consistent transcriptional signatures — early stress and detoxification pathways — that serve as the “memory” of biological failure.

3. Structured Negative Evidence (Boundary Definition)

The most underutilized strategic asset is structured failure at scale. The ECOTOX Knowledgebase provides a curated repository of biological failure across species and environments. By integrating this “power of no,” models transition from predicting outcomes to defining the exact boundaries of chemical and biological space.

4. Mechanistic Continuity

Resources like MiMeDB 2.0 bridge the gap between environmental exposure and host-level biochemical responses. These datasets provide the causal links required to move the industry from simple correlation to true mechanistic understanding.

Mapping the “Power of No” with Your Datasets

These datasets provide the structural and experimental “negative signals” for lifesciences:

DUD-E (Database of Useful Decoys): This aligns with the need to establish Precise Decision Boundaries. By pairing actives with decoys that have similar physical properties but are inactive, it helps models learn exactly where a scaffold transitions from “therapeutic” to “failure”.

MUV (Maximum Unbiased Validation): This addresses the Data-Composition Problem mentioned in the text. Because it uses “true inactives” from experimental bioassays, it helps eliminate the Structural Bias where models overfit to known scaffolds.

LIT-PCBA: This dataset provides the High-Quality Internal Data described in Table 1. Its focus on experimentally determined inactives provides a “high-fidelity map of failure” that helps de-risk lead candidates.

ChemDiv: These help define “No-Go Zones” in chemical space. By providing a balanced representation of active and inactive compounds, they directly reduce the False Positive rates that plague models trained on success-only data

One Health Unifying Architecture

One Health is the recognition that human health is inextricably linked for integrating:

• host biology
• microbiome
• environmental exposure
• and chemical perturbation

While the industry is not there yet, the path to “P4 medicine” (Predictive, Preventive, Personalized, Participatory) leads here. A One Health framework integrates data layers that are currently siloed:

1. Cross-Species Systems Biology: Using “vetinformatics” to identify conserved pathways across humans and animals, potentially identifying zoonotic threats and therapeutic targets long before they reach the clinic.
2. Environmental Context: Integrating real-time environmental metrics with clinical phenotypes to understand how external stressors — from pollution to climate — impact drug efficacy.
3. Real-Time Surveillance: Using the logic of remote sensing to power digital biomarkers and continuous patient monitoring, treating the patient as a dynamic ecosystem rather than a static snapshot.

To understand how this ecosystem-level data functions in practice, we can look at a clinical scenario.

SECTION 04 · PATIENT CASE STUDY
From Habitat to Healthcare: What House M.D. Forecasted That Our Models Don’t

For eight seasons, House M.D. ran one of the most quietly radical arguments in the history of medical television: the answer is almost never in the chart. It’s in the house. The show used this premise as a dramatic device — but the underlying diagnostic logic maps directly onto a real gap in pharmaceutical AI.

Get Partex.AI’s stories in your inbox

Join Medium for free to get updates from this writer.

Remember me for faster sign in

The insight is simple: patients are not closed biological systems; they are shaped by where they live, what they are exposed to, and how those exposures accumulate over time. What was once framed as an “environmental scan” is now becoming a measurable, data-driven reality.

In modern clinical settings, this insight remains underutilized. Consider a patient presenting with lack of efficacy and severe gastrointestinal toxicity to a well-characterized drug. Standard variables — dose, target, and pharmacokinetics — are all within expected ranges, yet the outcome is unexplained. These effects are not captured in conventional clinical datasets, creating a structural blind spot in both experimental design and AI models.

When analyzed through a One Health lens, the same case becomes easier to interpret mechanistically. Integrating cross-domain signals from resources such as ECOTOX Knowledgebase, MiMeDB 2.0, and transcriptional response datasets like LINCS L1000 can reveal a plausible systems-level chain of events. Environmental exposures may reshape the gut microbiome; reductions in butyrate-producing bacteria can destabilize metabolic homeostasis; microbial enzymes may biotransform a drug into reactive metabolites; and early transcriptional stress signatures can emerge before overt toxicity becomes clinically visible. In this view, what appears as an idiosyncratic clinical failure may instead reflect a predictable systems response once environmental, microbial, and cellular signals are analyzed together.

This reframing is not hypothetical — it is consistent with documented clinical phenomena. A well-known example is the interaction between the cardiac drug Digoxin and the gut bacterium Eggerthella lenta. In certain patients, microbial metabolism inactivates digoxin, leading to reduced therapeutic efficacy; in others, absence of this microbial activity results in higher systemic exposure and potential toxicity. Crucially, this variability is not explained by human genomics or standard pharmacokinetics alone, but by microbiome composition and function. Similar principles are observed in chemotherapy metabolism, where microbial enzymes can convert drugs into toxic intermediates within the gut, driving gastrointestinal side effects independent of dose.

Environmental exposures further compound these effects. Studies have shown that chronic exposure to organophosphates and other environmental chemicals can alter gut microbial ecology and intestinal barrier function, indirectly modulating drug metabolism pathways (as demonstrated in preclinical studies such as Joly Condette et al., 2014), and to disrupt colonization resistance mechanisms critical for microbial balance (Buffie & Pamer, 2013). Environmental toxicology datasets such as ECOTOX systematically capture these cross-species biochemical disruptions, while microbiome resources map their metabolic consequences. The gap, therefore, is not evidence but integration.

These observations suggest that drug response is influenced by a combination of host, microbial, and environmental factors that are not captured in conventional models.

SECTION 05 · THE EMERGING OPPORTUNITY
What Becomes Possible: Opportunities Beyond the Current Paradigm

The failure-informed, cross-domain approach unlocks a set of discovery capabilities that are structurally inaccessible to models trained on success alone.

1. Precision Toxicology from First Principles
By integrating transcriptomic stress signatures, ecotoxicological failure patterns, and microbial metabolomics, it becomes possible to build context-aware toxicity models — ones that predict not just whether a compound is toxic, but in whom, under what environmental conditions, and through which metabolic pathway. This transforms ADMET prediction from a population-level heuristic to a patient-level inference.

2. Cross-Species Target Discovery via Conserved Biology
Metagenomics reveals that environmental microbiomes and the human gut share conserved functional modules — enzymes such as nitroreductases and sulfatases that govern chemical transformations across domains. A compound that fails in a soil microbiome may interfere with the same enzymatic pathways in the human gut. Environmental failure datasets are, in effect, previously untapped training signals for human drug discovery.

3. Ecosystem-Level Toxicity Mapping
High-biodiversity ecosystems exhibit greater chemical stability, lower toxicity propagation, and reduced pathogen spillover. Conversely, disturbed ecosystems act as high-resolution maps of biological stress. By correlating chemical exposure with ecosystem disruption patterns, it becomes possible to construct network-level toxicity maps — context-aware representations that current models cannot generate.

4. Real-Time Environmental Pharmacovigilance
As environmental monitoring datasets grow in resolution and coverage, an opportunity emerges to link real-world exposure signals to clinical outcomes in near-real-time — a continuous learning system in which environmental signals update drug response models before safety signals emerge in clinical populations.

5. Bridging the Phenotype–Genotype Gap in Omics
AI models that leverage balanced success-and-failure datasets can distinguish meaningful biomarkers from biological noise. Historical failure context provides the contrastive signal necessary to validate that a molecular signature is biologically robust — not merely statistically significant in a narrow dataset.

SECTION 06 · ADOPTION PATHWAY
One Health AI Maturity Framework (OH-AI) for Adoption — 2026

Transitioning to a failure-informed, One Health data paradigm is not a binary shift. It is an incremental capability build. The following framework describes four levels of organisational maturity, with clear articulation of what each level unlocks.

Why this wins commercially

Why this wins commercially

• Higher success rates: Learns from failure → reduces late-stage clinical attrition
• Lower R&D cost: Fewer wet-lab cycles by filtering bad candidates early
• Faster timelines: Eliminates weak compounds sooner → faster pipeline progression
• Better predictions: Improves ADMET and toxicity accuracy using failure signals
• Regulatory advantage: Mechanistic + interpretable → aligns with AI scrutiny trends
• Stronger IP: Enables discovery of novel, non-obvious targets
• Data moat: Uses proprietary failure data that competitors don’t have
• Lower risk: Detects failure early → avoids expensive late-stage losses

Conclusion: Learning from Holistic Biology

The next generation of drug discovery models will not be trained solely on curated clinical success. They will learn from soil ecosystems, environmental toxicology, microbial networks, and cross-species biological responses. They will learn from failure.

What we now need to encode into our models: that the patient is not separable from their world.

“In biology, success is rare. But failure is abundant, structured, and — if we choose to learn from it — extraordinarily informative.”

At Partex, this is not a speculative future. It is an operational necessity. The Unified Biosystem is the thesis: that human health, environmental biology, and microbial ecosystems must be understood as a single, integrated data map. Until we build models that reflect that reality, the 90% attrition rate will remain.

Turning failure into training data directly improves probability of success, reduces cost, and accelerates drug development.

Contact Partex.AI to discuss how evidence-based AI in life science can accelerate your specific drug discovery use case in 2026. Subscribe to our newsletter for insights on AI maturity, data strategy, and innovation in healthcare R&D.

AUTHOR BIOS

Dr. Rachana Nagar, Scientific Manager & AI-Driven Drug Discovery Expert

Dr. Nagar specializes in molecular genetics, cancer biology, and AI-driven drug discovery, with a focus on biomarker discovery and translational research. At Partex, she leads cross-functional AI-powered pharma projects to enhance R&D efficiency and decision-making. With experience at Stony Brook University and a PhD from Banaras Hindu University, she integrates science and data to advance precision medicine.

Dr. Sanyogita Purandare, VP of Data Science

Dr. Purandare is an expert in AI-driven drug discovery, specializing in multimodal learning, generative AI, and predictive modeling. She has developed differentiating AI models that accelerate drug development and optimize pharmaceutical R&D. With leadership roles at global pharma, biotech, and manufacturing corporations, she has delivered AI solutions that reduced costs and improved efficiency. She holds a PhD in Generative AI from the University of Illinois Urbana-Champaign (ECE) and is an alumna of IIT Delhi. Recognized among GlantorX’s 100 Faces Women Leaders, she has a proven ability to lead cross-functional teams and drive AI innovation.

ACKNOWLEDGEMENT OF REVIEWERS

This article greatly benefited from the insightful reviews and feedback provided by:

Dr. Gunjan Bhardwaj, Founder & CEO at Partex.AI

Gunjan is a recognised global leader in AI & Life Sciences. He has various patents and has authored two books, as well as published articles in prestigious journals including Harvard Business Review and MIT Sloan Review. Gunjan studied at IIT Bombay and the European Business School, Germany. He has served on the advisory boards of various pharmaceutical companies, think tanks, and not-for-profits, and has been honoured with awards including Germany’s ’40 under 40’ by Capital Magazine and the ‘Leader of the future reality’ by BCG-Handelsblatt.

Gaurav Tripathi, Co-founder & CTO at Partex.AI

Gaurav Tripathi is a serial entrepreneur, co-founder, and Group CTO at Partex.AI. He has 19+ years of experience across startups spanning video, big data, blockchain, and AI, and is an inventor on 45 of the 175+ patents filed under his leadership. An IIT Bombay alumnus, his leadership has earned him accolades including the Warrior of Change Award, Business World Disrupt 40 Under 40, and the Global Spin Award for Digital Transformation Leader of the Year.

References

[1] Sun D, et al. “Why 90% of clinical drug development fails and how to improve it?” Acta Pharmaceutica Sinica B. 2022; 12(7):3049–3062.

[2] Schneider P, et al. “Rethinking drug design in the artificial intelligence era.” Nature Reviews Drug Discovery. 2020; 19:353–364.

[3] Mullowney MW, et al. “Artificial intelligence for natural product drug discovery.” Nature Reviews Drug Discovery. 2023; 22:895–916.

[4] Zinsstag J, et al. (eds). “One Health: The Theory and Practice of Integrated Health Approaches.” CABI. 2015.

[5] Qin J, et al. “A human gut microbial gene catalogue established by metagenomic sequencing.” Nature. 2010; 464:59–65.

[6] Subramanian A, et al. “A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.” Cell. 2017; 171(6):1437–1452.

[7] Zimmermann M, et al. “Mapping human microbiome drug metabolism by gut bacteria and their genes.” Nature. 2019; 570:462–467.

[8] Wishart DS, et al. “MiMeDB: the Human Microbial Metabolome Database.” Nucleic Acids Research. 2023; 51(D1):D611–D620.

[9] US Environmental Protection Agency. “ECOTOX Knowledgebase.” 2024. https://cfpub.epa.gov/ecotox/

[10] Joly Condette C, et al. “Increased Intestinal Permeability after Chronic Chlorpyrifos Exposure in Rats.” PLoS ONE. 2014; 9(7):e102217.

[11] Buffie CG, Pamer EG. “Microbiota-mediated colonization resistance against intestinal pathogens.” Nature Reviews Immunology. 2013; 13:790–801.

[12] Sonnenburg JL, Bäckhed F. “Diet–microbiota interactions as moderators of human metabolism.” Nature. 2016; 535:56–64.

[13] Shore D (creator). House M.D. Fox Broadcasting. 2004–2012. Cited for critical commentary on diagnostic reasoning in clinical medicine.

[14] Muhummed AM, Lanker KC, Yersin S, Zinsstag J, Vonaesch P. One Health, One Microbiome. Microbiome. 2025 Oct 23;13(1):216. doi: 10.1186/s40168–025–02231–6. PMID: 41131551; PMCID: PMC12548117.

[15] “One Health Microbiome Center”, https://www.huck.psu.edu/institutes-and-centers/microbiome-center.